Category: Include on Menu

  • Novartis shares edge higher after ianalumab hits key goals in Phase 3 trial

    Novartis shares edge higher after ianalumab hits key goals in Phase 3 trial

    Novartis (NYSE:NVS) announced that its investigational antibody, ianalumab, combined with eltrombopag, successfully met the primary endpoint in a Phase 3 study (VAYHIT2) involving patients with primary immune thrombocytopenia (ITP). The therapy notably prolonged the time until treatment failure, assessing how long patients maintained safe platelet counts during and after treatment. Following the news, Novartis shares…

  • Ford Issues Recall for Over 103,000 Vehicles Over Axle Hub Spline Defect

    Ford Issues Recall for Over 103,000 Vehicles Over Axle Hub Spline Defect

    Ford Motor Company (NYSE:F) is recalling 103,174 vehicles across the U.S. due to a potential safety defect involving damaged axle hub splines, the National Highway Traffic Safety Administration (NHTSA) reported. The recall stems from concerns that affected vehicles might roll away if placed in park without the parking brake engaged. Additionally, the damaged axle hub…

  • AST SpaceMobile Shares Surge 13% Premarket Following Satellite Launch Update

    AST SpaceMobile Shares Surge 13% Premarket Following Satellite Launch Update

    AST SpaceMobile (NASDAQ:ASTS) saw its shares climb by 13% in early U.S. trading on Tuesday after the company announced a revised schedule for launching its next set of BlueBird satellites. The firm, which specializes in satellite-to-smartphone connectivity, aims to build a high-speed cellular broadband network by deploying its constellation of low-Earth-orbit BlueBird satellites. Notable investors…

  • U.S. Stocks Finish Choppy Trading Day Moderately Lower

    U.S. Stocks Finish Choppy Trading Day Moderately Lower

    Following the strong upward move seen in the previous week, stocks showed a lack of direction over the course of the trading session on Monday. The major averages spent the day bouncing back and forth across the unchanged line. The major averages eventually ended the day in negative territory. While the slid 200.52 points or…

  • Viatris Shares Climb Following FDA Clearance of First Generic Iron Sucrose Injection

    Viatris Shares Climb Following FDA Clearance of First Generic Iron Sucrose Injection

    Viatris Inc (NASDAQ:VTRS) saw its stock increase by 2.6% after the U.S. Food and Drug Administration approved its Iron Sucrose Injection, USP, marking the first generic alternative to Venofer® Injection. This intravenous iron replacement therapy is prescribed for iron deficiency anemia in both adult and pediatric patients suffering from chronic kidney disease. The product will…

  • VivoPower Shares Jump After Announcement to Acquire Ripple Labs Equity

    VivoPower Shares Jump After Announcement to Acquire Ripple Labs Equity

    VivoPower International PLC (NASDAQ:VVPR) saw its stock climb 9% following news of its intent to acquire shares in Ripple Labs, enhancing its strategy centered around XRP digital assets in its treasury. The company has allocated an initial $100 million to buy privately held Ripple shares after completing a two-month due diligence process. These purchases remain…

  • Amphastar Shares Rise Following FDA Approval of Generic Iron Sucrose Injection

    Amphastar Shares Rise Following FDA Approval of Generic Iron Sucrose Injection

    Amphastar Pharmaceuticals (NASDAQ:AMPH) saw its stock increase by 4% after the company announced that the FDA had approved its generic version of iron sucrose injection, a treatment used for iron deficiency anemia in patients with chronic kidney disease. The newly authorized medication, formerly known as AMP-002, will be offered in three dosage strengths: 50mg/2.5mL, 100mg/5mL,…

  • IO Biotech Shares Climb Following Encouraging Cancer Vaccine Trial Results

    IO Biotech Shares Climb Following Encouraging Cancer Vaccine Trial Results

    IO Biotech (NASDAQ:IOBT) stock gained 6.1% after revealing topline data from its pivotal Phase 3 trial evaluating Cylembio, an experimental cancer vaccine, combined with Merck’s (NSE:PROR) KEYTRUDA in patients with advanced melanoma. The study demonstrated clinical benefits in progression-free survival (PFS) for the combination treatment versus KEYTRUDA alone, though it narrowly fell short of statistical…

  • Nyxoah Shares Climb Following FDA Clearance of Genio Device for Sleep Apnea Treatment

    Nyxoah Shares Climb Following FDA Clearance of Genio Device for Sleep Apnea Treatment

    Nyxoah SA (NASDAQ:NYXH) saw its stock rise 9.4% after the FDA granted approval for its Genio system designed to treat moderate to severe obstructive sleep apnea (OSA). The Belgium-based medtech firm secured marketing authorization for its cutting-edge hypoglossal nerve stimulation (HGNS) device, intended for patients with an Apnea-Hypopnea Index (AHI) ranging from 15 to 65.…

  • Intel Shares Climb as CEO Gears Up for White House Meeting Amid Trump’s Call for Resignation

    Intel Shares Climb as CEO Gears Up for White House Meeting Amid Trump’s Call for Resignation

    Intel (NASDAQ:INTC) stock edged up 3% Monday morning, recovering some of its recent losses as CEO Lip-Bu Tan prepares to meet with President Trump at the White House. This comes after Trump publicly demanded Tan’s resignation last week. The Wall Street Journal reports that Tan is scheduled to meet with Trump on Monday to address…